Cardio Diagnostics Holdings (CDIO) Assets Average (2022 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Assets Average of $8.7 million for Q1 2026, up 4.65% sequentially from $8.3 million in Q4 2025, and down 24.33% YoY from $11.4 million in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Assets Average (2022 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Assets Average for 5 years, with the latest figure at $8.7 million in Q1 2026.
- Quarterly Assets Average fell 24.33% year-over-year to $8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.7 million (down 24.33% YoY) and the FY2025 annual result came in at $9.2 million, up 21.91% from the prior year.
- Assets Average advanced to $8.7 million in Q1 2026 per CDIO's latest filing, from $8.3 million in the prior quarter.
- Over five years, Assets Average peaked at $65.5 million in Q3 2022 and troughed at $4.2 million in Q2 2024.
- A 5-year average of $17.4 million and a median of $8.3 million in 2025 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2025: Assets Average slumped 90.29% in 2023, then surged 172.44% in 2025.
- Over 5 years, Assets Average stood at $36.0 million in 2022, then sank by 85.53% to $5.2 million in 2023, then surged by 44.8% to $7.5 million in 2024, then gained by 9.66% to $8.3 million in 2025, then advanced by 4.65% to $8.7 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $8.7 million, $8.3 million, and $9.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.50 Bn | 131.65 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.10 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.59 Bn | 60.41 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.75 Bn | 51.62 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.80 Bn | 9.41 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 19.82 Bn |
| 10 | Cardio Diagnostics Holdings | 6.14 Mn | 554,201.32 | - | 8.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.74 Mn |
| Mar 31, 2026 | 8.66 Mn |
| Dec 31, 2025 | 8.28 Mn |
| Sep 30, 2025 | 9.59 Mn |
| Jun 30, 2025 | 11.34 Mn |
| Mar 31, 2025 | 11.45 Mn |
| Dec 31, 2024 | 7.55 Mn |
| Sep 30, 2024 | 4.24 Mn |
| Jun 30, 2024 | 4.16 Mn |
| Mar 31, 2024 | 4.39 Mn |
| Dec 31, 2023 | 5.21 Mn |
| Sep 30, 2023 | 6.36 Mn |
| Jun 30, 2023 | 7.65 Mn |
| Mar 31, 2023 | 7.40 Mn |
| Dec 31, 2022 | 36.03 Mn |
| Sep 30, 2022 | 65.50 Mn |
| Jun 30, 2022 | 65.42 Mn |
| Mar 31, 2022 | 33.37 Mn |